SEARCH

SEARCH BY CITATION

References

  • BENMOUYAL, E., COTE, G. & MORIN, Y. (1971). A direct action of Δ9-tetra-hydrocannabinol on myocardial contractility. Clin. Res., 19, 758.
  • BEVAN, S., HOTHI, S., HUGHES, G., JAMES, I.F., RANG, H.P., SHAH, K., WALPOLE, C.S. & YEATS, J.C. (1992). Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. Br. J. Pharmacol., 107, 544552.
  • BISOGNO, T., MAURELLI, S., MELCK, D., DE PETROCELLIS, L. & DI MARZO, V. (1997). Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem., 272, 33153323.
  • CALIGNANO, A., LA RANA, G., BELTRAMO, M., MAKRIYANNIS, A. & PIOMELLI, D. (1997). Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur. J. Pharmacol., 337, R1R2.
  • CALIGNANO, A., LA RANA, G., GIUFFRIDA, A. & PIOMELLI, D. (1998). Control of pain initiation by endogenous cannabinoids. Nature, 394, 277281.
  • CHIN, C.N., MURPHY, J.W., HUFFMAN, J.W. & KENDALL, D.A. (1999). The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J. Pharmacol. Exp. Ther., 291, 837844.
  • CRAIB, S.J., ELLINGTON, H.C., PERTWEE, R.G. & ROSS, R.A. (2001). A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br. J. Pharmacol., 134, 3037.
  • DEUTSCH, D.G. & CHIN, S.A. (1993). Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol., 46, 791796.
  • DEUTSCH, D.G., GOLIGORSKY, M.S., SCHMID, P.C., KREBSBACH, R.J., SCHMID, H.H.O., DAS, S.K., DEY, S.K., ARREAZA, G., THORUP, C., STEFANO, G. & MOORE, L.C. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. J. Clin. Invest., 100, 15381546.
  • DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 19461949.
  • DI MARZO, V., FONTANA, A., CADAS, H., SCHINELLI, S., CIMINO, G., SCHWARTZ, J.C. & PIOMELLI, D. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372, 686691.
  • ELLIS, E.F., MOORE, S.F. & WILLOUGHBY, K.A. (1995). Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. Am. J. Physiol., 269, H1859H1864.
  • FACCI, L., DAL TOSO, R., ROMANELLO, S., BURIANI, A., SKAPER, S.D. & LEON, A. (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U.S.A., 92, 33763380.
  • FULTON, D. & QUILLEY, J. (1998). Evidence against anandamide as the hyperpolarizing factor mediating the nitric oxide-independent coronary vasodilator effect of bradykinin in the rat. J. Pharmacol. Exp. Ther., 286, 11461151.
  • GATLEY, S.J., LAN, R., VOLKOW, N.D., PAPPAS, N., KING, P., WONG, C.T., GIFFORD, A.N., PYATT, B., DEWEY, S.L. & MAKRIYANNIS, A. (1998). Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J. Neurochem., 70, 417423.
  • GEBREMEDHIN, D., LANGE, A.R., CAMPBELL, W.B., HILLARD, C.J. & HARDER, D.R. (1999). Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+channel current. Am. J. Physiol., 276, H2085H2093.
  • HARRIS, D., KENDALL, D.A. & RANDALL, M.D. (1999). Characterization of cannabinoid receptors coupled to vasorelaxation by endothelium-derived hyperpolarizing factor. Naunyn Schmiedebergs Arch. Pharmacol., 359, 4852.
  • HILLARD, C.J., EDGEMOND, W.S., JARRAHIAN, A. & CAMPBELL, W.B. (1997). Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem., 69, 631638.
  • HILLARD, C.J., MANNA, S., GREENBERG, M.J., DICAMELLI, R., ROSS, R.A., STEVENSON, L.A., MURPHY, V., PERTWEE, R.G. & CAMPBELL, W.B. (1999). Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther., 289, 14271433.
  • HOSOHATA, Y., QUOCK, R.M., HOSOHATA, K., MAKRIYANNIS, A., CONSROE, P., ROESKE, W.R. & YAMAMURA, H.I. (1997). AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain. Eur. J. Pharmacol., 321, R1R3.
  • HUY, N.D., MCNICHOLL, J. & ROY, P.E. (1972). The acute effects of Δ9-tetrahydrocannabinol (THC) on the left ventricular function of isolated hearts., Clin. Res., 20, 910.
  • JÁRAI, Z., WAGNER, J.A., GOPARAJU, S.K., WANG, L., RAZDAN, R.K., SUGIURA, T., ZIMMER, A.M., BONNER, T.I., ZIMMER, A. & KUNOS, G. (2000). Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice. Hypertension, 35, 679684.
  • JÁRAI, Z., WAGNER, J.A., VARGA, K., LAKE, K.D., COMPTON, D.R., MARTIN, B.R., ZIMMER, A.M., BONNER, T.I., BUCKLEY, N.E., MEZEY, E., RAZDAN, R.K., ZIMMER, A. & KUNOS, G. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A., 96, 1413614141.
  • JARRAHIAN, A. & HILLARD, C.J. (1997). Arachidonylethanolamide (anandamide) binds with low affinity to dihydropyridine binding sites in brain membranes. Prostaglandins Leukot. Essent. Fatty Acids, 57, 551554.
  • LAGNEUX, C. & LAMONTAGNE, D. (2001). Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br. J. Pharmacol., 132, 793796.
  • LAKE, K.D., COMPTON, D.R., VARGA, K., MARTIN, B.R. & KUNOS, G. (1997). Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J. Pharmacol. Exp. Ther., 281, 10301037.
  • LAY, L., ANGUS, J.A. & WRIGHT, C.E. (2000). Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse. Eur. J. Pharmacol., 391, 151161.
  • MANNO, B.R. & MANNO, J.E. (1973). Some cardiovascular actions of Δ9-tetrahydrocannabinol in the rat. Toxicol. Appl. Pharmacol., 25, 451456.
  • MATSUDA, L.A., LOLAIT, S.J., BROWNSTEIN, M.J., YOUNG, A.C. & BONNER, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561564.
  • MECHOULAM, R., BEN-SHABAT, S., HANUS, L., LIGUMSKY, M., KAMINSKI, N.E., SCHATZ, A.R., GOPHER, A., ALMOG, S., MARTIN, B.R., COMPTON, D.R., PERTWEE, R.G., GRIFFIN, G., BAYEWITCH, M., BARG, J. & VOGEL, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 50, 8390.
  • MUNRO, S., THOMAS, K.L. & ABU-SHAAR, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 6165.
  • NAHAS, G. & TROUVE, R. (1985). Effects and interactions of natural cannabinoids on the isolated heart. Proc. Soc. Exp. Biol. Med., 180, 312316.
  • PERTWEE, R.G. (2000). Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin. Investig. Drugs, 9, 15531571.
  • PRATT, P.F., HILLARD, C.J., EDGEMOND, W.S. & CAMPBELL, W.B. (1998). N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am. J. Physiol., 274, H375H381.
  • RANDALL, M.D., ALEXANDER, S.P., BENNETT, T., BOYD, E.A., FRY, J.R., GARDINER, S.M., KEMP, P.A., MCCULLOCH, A.I. & KENDALL, D.A. (1996). An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem. Biophys. Res. Commun., 229, 114120.
  • RANDALL, M.D. & KENDALL, D.A. (1997). Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur. J. Pharmacol., 335, 205209.
  • RINALDI-CARMONA, M., BARTH, F., HEAULME, M., SHIRE, D., CALANDRA, B., CONGY, C., MARTINEX, S., MARUANI, J., NELIAT, G., CAPUT, D., FERRARA, P., SOUBIRE, P., BRELIERE, J.C. & LEFUR, G. (1996). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 350, 240244.
  • RINALDI-CARMONA, M., BARTH, F., MILLAN, J., DEROCQ, J.M., CASELLAS, P., CONGY, C., OUSTRIC, D., SARRAN, M., BOUABOULA, M., CALANDRA, B., PORTIER, M., SHIRE, D., BRELIERE, J.C. & LE FUR, G.L. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 284, 644650.
  • ROSS, R.A., BROCKIE, H.C., STEVENSON, L.A., MURPHY, V.L., TEMPLETON, F., MAKRIYANNIS, A. & PERTWEE, R.G. (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol., 126, 665672.
  • SHOWALTER, V.M., COMPTON, D.R., MARTIN, B.R. & ABOOD, M.E. (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther., 278, 989999.
  • SMART, D., GUNTHORPE, M.J., JERMAN, J.C., NASIR, S., GRAY, J., MUIR, A.I., CHAMBERS, J.K., RANDALL, A.D. & DAVIS, J.B. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol., 129, 227230.
  • SMILEY, K.A., KARLER, R. & TURKANIS, S.A. (1976). Effects of cannabinoids on the perfused rat heart. Res. Commun. Chem. Pathol. Pharmacol., 14, 659675.
  • SUGIURA, T., KONDO, S., SUKAGAWA, A., NAKANE, S., SHINODA, A., ITOH, K., YAMASHITA, A. & WAKU, K. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun., 215, 8997.
  • VARGA, K., LAKE, K., MARTIN, B.R. & KUNOS, G. (1995). Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol., 278, 279283.
  • WAGNER, J.A., VARGA, K., JARAI, Z. & KUNOS, G. (1999). Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension, 33, 429434.
  • WHITE, R. & HILEY, C.R. (1997). Endothelium and cannabinoid receptor involvement in levcromakalim vasorelaxation. Eur. J. Pharmacol., 339, 157160.
  • WHITE, R. & HILEY, C.R. (1998a). The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery. Br. J. Pharmacol., 125, 533541.
  • WHITE, R. & HILEY, C.R. (1998b). The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br. J. Pharmacol., 125, 689696.
  • WHITE, R., HO, W.-S.V., BOTTRILL, F.E., FORD, W.R. & HILEY, C.R. (2001). Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br. J. Pharmacol., 134, 921929.
  • ZYGMUNT, P.M., CHUANG, H., MOVAHED, P., JULIUS, D. & HOGESTATT, E.D. (2000). The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur. J. Pharmacol., 396, 3942.
  • ZYGMUNT, P.M., PETERSSON, J., ANDERSSON, D.A., CHUANG, H., SORGARD, M., DI MARZO, V., JULIUS, D. & HOGESTATT, E.D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400, 452457.